Royal DSM, the global Life Sciences and Materials Sciences company, today announces that its joint venture Jinling DSM Resins Co., Ltd. (JDR) will invest approximately € 50 million in a new production facility for composite resins in Nanjing, China. The new facility, which will replace the current facility, will be among the largest manufacturing plants for composite resins in the world. DSM's share in the investment is 75%.
The new facility will substantially strengthen the local position of the joint venture in the markets for composite materials in China. DSM holds 75% of the shares in JDR whereas Sinopec Assets Management Co. Ltd. holds 25% in the joint venture.
The expansion follows on the continued strong demand for high-end resins in all the application segments in the region. The new unit is expected to come on stream early 2012.

Nico Gerardu, Member of the DSM Managing Board and responsible for the Performance Materials cluster, said: "This investment perfectly fits in our strategy DSM in motion: driving focused growth. For several years in a row demand for composite resins in China has been larger than the capacity to produce. With this large investment in local manufacturing capacity DSM is preparing itself to take our growth in China in composite resins to the next level. It will also contribute to our 2015 target of doubling DSM's sales in China compared to 2010 to over USD 3 billion."

Dimitri de Vreeze, President DSM Resins, added: "With this new factory, in combination with the new R&D Center for composite materials in Shanghai which we announced in October 2010, we, together with our JV partner Sinopec look with confidence to a bright future ahead for our composite resins business in China."

This investment allows DSM to further drive its growth in China in sustainable, innovative solutions. Composite resins can create ecological benefits throughout the whole value chain (with end-markets such as transportation, wind energy, tanks, pipes & relining and building and construction) by reducing energy use, emissions and waste. Many of DSM's innovations in composite resins are ECO+ products - products and services that, when considered over their whole life cycle, offer clear ecological benefits compared to the mainstream solutions they compete with.

DSM in Composite Resins
DSM is the largest producer of structural resins in Europe and a technology and innovation leader for the composites industry. The company is globally expanding its activities in structural resins, especially in China and India, targeting high added-value segments. In China, DSM is the leader in specialty UPR and Vinyl ester resins. DSM is also the world's largest producer of glass fiber sizings & binders under the Neoxil® brand. DSM can claim unique competencies throughout the composites value chain. For more information: www.dsmcompositeresins.com.

DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com


DSM - proposed appointment to the Managing Board of Directors

The Supervisory Board of Royal DSM is pleased to announce that it will propose to the Annual General Meeting of Shareholders on 28 April 2011 to appoint Mr. Stefan Doboczky to the Managing Board of DSM with responsibility for DSM's Pharma cluster as well as the regional responsibility of DSM's activities in Asia, with effect from 1 May 2011.

Mr. Doboczky will operate from two office locations, in the Netherlands and in Asia in line with the further internationalization of DSM, as set out in the latest DSM strategy announced in September 2010.

Stefan Doboczky (1967), an Austrian national is at present President of the Business Group DSM Anti-Infectives. He has built a strong track record within the DSM Pharma cluster and has particular experience with business development in high growth economies, including Asia. Before joining DSM in 1998, Mr. Doboczky worked at ARCO Chemicals in Austria and the UK.

In DSM Mr. Doboczky held several senior positions in DSM Pharmaceutical Products, before he became Vice President and Business Unit Director China for DSM Anti-Infectives based in Beijing in 2006. In 2009 he became the President of DSM Anti-Infectives.

Mr. Doboczky studied at the Technical University of Vienna, Austria and he holds a Master in Chemistry and a PhD in Natural and Technical Sciences as well as an MBA from IMD in Lausanne.

In view of the ongoing formation of the joint venture between DSM Anti-Infectives and Sinochem, Mr. Doboczky will for the time being also continue in his position as President DSM Anti-Infectives.



DSM Successfully Completes Tender Offer for Martek and Expects to Complete Acquisition Today

Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company, announced today that it has successfully completed the subsequent offering period to its all-cash tender offer to purchase all of the outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

The previously announced subsequent offering period expired at 12:00 midnight, New York City time, on Thursday, February 24, 2011. The depositary for the tender offer has advised that, as of such time, a total of approximately 262,000 additional Martek shares of common stock had been validly tendered in the subsequent offering period, which, together with the shares validly tendered and not withdrawn during the initial offering period, resulted in DSM holding approximately 89.5% of Martek's currently outstanding shares. DSM has accepted for payment all validly tendered shares.

DSM intends to exercise the top-up option that was granted to DSM pursuant to the merger agreement to purchase additional shares directly from Martek and to complete a short-form merger in accordance with the merger agreement later today. In the short-form merger, Greenback Acquisition Corporation will be merged with and into Martek, and each share of Martek common stock not tendered in the tender offer, other than those as to which holders exercise appraisal rights under Delaware law and those held by DSM or Martek or their respective subsidiaries, will be converted in the merger into the right to receive $31.50 per share in cash, without interest and less any required withholding taxes. This is the same price per share paid in the tender offer.

Martek
Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. Martek's technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform has resulted in Martek's development of a number of products, including the company's flagship product, life'sDHA(TM), a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds. Martek also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula and follow-on formulas. Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: Culturelle®, a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief and detection of urinary tract infections; and Estroven®, the leading all-natural nutritional supplement brand addressing the symptoms of menopause.